Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer
Children's Oncology Group
60 participants
Feb 27, 2025
INTERVENTIONAL
Conditions
Summary
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Receive standard chemotherapy
Undergo blood sample collection
Ancillary studies
Ancillary studies
Given IM
Locations(193)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06513962